New drug duo aims to keep ovarian cancer at bay
NCT ID NCT06971744
Summary
This study is testing whether adding two existing drugs, hydroxychloroquine and nelfinavir, to standard maintenance therapy helps control ovarian cancer longer. It will involve 38 patients whose cancer has returned but initially responded well to platinum chemotherapy. The main goals are to see if the drug combination is safe and if it helps delay the cancer from progressing again.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.